• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Quick Take: Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER)

byArnav Agarwal, MDandAliya Ramjaun
September 30, 2019
in Cardiology, Chronic Disease, Nephrology
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

1. Potassium binder therapy with patiromer can promote longer duration of spironolactone use for resistant hypertension in the setting of chronic kidney disease.

Evidence Rating Level: 1 (Excellent)

Spironolactone is recommended in the treatment of resistant hypertension, however there is limited data regarding its use in the setting of chronic kidney disease (CKD). In CKD, where the use of spironolactone for resistant hypertension may be limited by the risk of developing hyperkalemia, there may be a role for potassium binders such as patiromer. In the AMBER trial, a phase II, multi-centre, randomized, double-blind trial, 295 participants with CKD and resistant hypertension were randomized to receive patiromer 8.4g once daily or placebo for 12 weeks to evaluate the safety and efficacy of patiromer therapy as an adjunct to spironolactone and baseline blood pressure medications in the treatment of resistant hypertension. The primary outcome was the between-group difference in proportions of patients using spironolactone at week 12. Researchers found that 86% and 66% of patiromer and placebo-group participants remained on spironolactone therapy at week 12, respectively (between-group difference 19.5%, 95% CI 10.0% to 29.0%, p<0.0001). Adverse events were minor and comparable between groups. This study therefore shows that patiromer therapy may facilitate prolonged use of spironolactone therapy in patients with CKD and resistant hypertension.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Tags: chronic kidney diseasehypertensionpatiromerpotassium binderspironolactone
Previous Post

Quick Take: Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY)

Next Post

2 Minute Medicine Rewind September 30, 2019

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

June 14, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

May 10, 2025
#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death
StudyGraphics

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

April 17, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

App-based physical activity intervention may have a limited role among women with prior hypertensive pregnancy disorder

April 11, 2025
Next Post
2 Minute Medicine Rewind September 30, 2019

2 Minute Medicine Rewind September 30, 2019

Parent/child feeding practices associated with weight status

Diet trends over the past two decades in the United States

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
  • The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.